

Confirmed Speakers

Plenary Speakers

PL12 - Partnering Early to Better Serve Patients Suffering from Rare and Devastating Diseases



Jean-Philippe ANNÉREAU
(ALEXION, Paris, France)

PL19 - Identifying High Quality, Potent and Selective Inhibitors of ATM Kinase for Oncology Therapies: Discovery of AZD0156



Bernard BARLAAM
(ASTRAZENECA, Cambridge, United Kingdom)

PL02 - Peptide Drugs to Target GPCR- State of the Art and Innovative Application



Annette BECK-SICKINGER
(LEIPZIG UNIVERSITY, Leipzig, Germany)

PL06 - Discovery of PF-06840003, a Novel IDO Inhibitor for Cancer Immunotherapy



Stefano CROSIGNANI
(ITEOS THERAPEUTICS SA, Gosselies, Belgium)

PL01 - Sugars & Proteins: Glycomimetics to Target Infectious Disease



Benjamin DAVIS
(OXFORD UNIVERSITY, Oxford, United Kingdom)

PL22 - Creating, Varying and Selecting : The Driving Forces in Drug Discovery and Chemical Biology Pierre Fabre Award lecture



Benoît DEPREZ
(INSTITUT PASTEUR OF LILLE, Lille, France)

PL08 - Expanding Screening Decks by Innovative MCR Scaffolds



Alexander DÖMLING
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

PL14 - Xeno Nucleic Acids (XNA) *in vivo* : A New Medicinal Chemistry Approach?



Piet HERDEWIJN
(KU LEUVEN, Leuven, Belgium)

PL15 - Monitoring the Antagonist-Protein and Protein-Protein Interactions with NMR and X-ray: Inhibitors of the p53-Mdm2 and Immune Checkpoint PD-1/PD-L1 Interactions

Confirmed Speakers



Tad HOLAK
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Krakow, Poland)

PL17 - Engineering Alfabodies to Generate Potent Druggable Inhibitors of Intracellular Protein-Protein Interactions



Ignace LASTERS
(COMPLIX, Zwijnaarde, Belgium)

PL20 - Raising the Gold Standard: Design & Development of Highly Selective JAK3 Probes (Janus Kinase 3)



Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany)

PL04 - Immunotherapy of Cancers: The Lessons of Oncodermatology; Melanoma as a Model



Nicolas MEYER
(ONCOPOLE TOULOUSE, Toulouse, France)

PL03 - Small Molecule Approaches in Immune Modulation in Cancer.



Ronan O'HAGAN
(MERCK, SHARP & DOHME, Boston, United States)

PL09 - First-in-class Extracellular Modulators of Receptor Tyrosine Kinases: from Theory to Practice



Didier ROGNAN
(CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France)

PL13 - Allosteric Inhibitors of Dengue and Zika Virus NS3/NS2B Proteases



Tanja SCHIRMEISTER
(UNIVERSITY OF MAINZ, Mainz, Germany)

PL07 - De Novo Drug Design — Inspiration from Nature



Gisbert SCHNEIDER
(ETH ZÜRICH, Zürich, Switzerland)

PL11 - Structure-based Drug Design (SBDD) in Medicinal Chemistry-enabled Drug Discovery



Hong SHEN
(ROCHE INNOVATION CENTER, Shanghai, China)

Confirmed Speakers

PL21 - Leniolisib (CDZ173) - Discovery of a New Generation of Potent and Selective PI3K γ Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases



Nicolas SOLDERMANN
(NOVARTIS, Basel, Switzerland)

PL16 - Bioactive Ribosomal and Non-Ribosomal Peptides from Nature - Structures, Biosynthesis and Engineering Options



Roderich D. SÜSSMUTH
(TECHNICAL UNIVERSITY BERLIN, Berlin, Germany)

PL10 - Chemoselective and Biocompatible Reactions, New Tools for Heterocyclic Chemistry and Chemical Biology



Frédéric TARAN
(CEA/SACLAY, Gif-sur-Yvette, France)

PL18 - Development of Dual IGF1R/INSR Inhibitors - A Case Study



Heather TYE
(EVOTEC LTD, Abingdon, United Kingdom)

PL05 - Novel Small Molecule MerTK Inhibitors and their Biological Uses



Xiaodong WANG
(UNIVERSITY OF NORTH CAROLINA, Chapel Hill, United States)

Keynote Speakers

KL07 - Nanometric Micelles for *in vivo* Imaging and Drug Delivery



Eric DORIS
(CEA, Gif-sur-Yvette, France)

KL03 - Post-functionalization of RNAs for Specific Conjugations with Peptides and Proteins



Mélanie ETHEVE-QUELQUEJEU
(UNIVERSITY PARIS DESCARTES, Paris, France)

KL05 - Copper and Zinc as Therapeutic Players in Alzheimer's Disease: With a little Help from Coordination Chemistry.



Christelle HUREAU
(LCC CNRS, Toulouse, France)

KL04 - Discovery of CDK8/CDK19 Kinase Modulators and Evaluation of their Therapeutic Potential

Confirmed Speakers



Aurelie MALLINGER
(INSTITUTE OF CANCER RESEARCH, London, United Kingdom)

KL02 - Mnk1/2 Kinase Inhibitors for the Treatment of Leukemia



Kassoum NACRO
(EXPERIMENTAL THERAPEUTICS CENTER, Singapore, Singapore)

KL06 - Discovery of Novel TACE Inhibitors for Topical Treatment of Psoriasis



Gilles OUVRY
(GALDERMA R&D, Sophia Antipolis, France)

KL08 - Mining from NP-Like Fragments in 3D: Discovery of a Potent Caspase-1 Inhibitor



Vincent RODESCHINI
(EDELIRIS, LYON, France)

KL01 - New Modalities inspired by nature: from Genetic Encoding of Cyclic Peptides to Hybrid Macrocycles



Eric VALEUR
(ASTRAZENECA, IMED BIOTECH UNIT, Cambridge, United States)